BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34528449)

  • 21. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
    Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
    Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
    Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
    Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erratic enteric absorption of dolutegravir in a critically ill patient.
    de Antonio-Cuscó M; Parrilla FJ; Knobel Freud H; Echeverría-Esnal D; Castellví Font A; Vázquez A; Masclans JR; Ferrández O; Grau S
    Rev Esp Quimioter; 2022 Aug; 35(4):408-410. PubMed ID: 35644951
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
    Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
    Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
    Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
    World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
    Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
    Li J; Yu Q; Fu S; Xu M; Zhang T; Xie C; Feng J; Chen J; Zang A; Cai Y; Fu Q; Liu S; Zhang M; Hong Q; Huang L; Yuan X
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1621-8. PubMed ID: 27160286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
    Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
    Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
    Israel S; Elinav H; Elazary R; Porat D; Gibori R; Dahan A; Azran C; Horwitz E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
    Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
    Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
    Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
    World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
    Laker EAO; Arinaitwe A; Owarwo N; Onzia A; Nasasira B; Wailagala A; Kalule I; Anguzu G; Kiragga A; Seden K; Lwanga I; Castelnuovo B; Musomba R; Lamorde M
    Drug Saf; 2020 Nov; 43(11):1133-1140. PubMed ID: 32926356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

  • 40. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.